483
Hubei JXBio Pharmaceutical Co., LtdFDA 483 - Hubei JXBio Pharmaceutical Co., Ltd - August 30, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Hubei JX Bio Pharmaceutical Co., Ltd. in Xianning, China, revealed significant deficiencies across quality, facility, and production operations. The firm was cited for inadequate personnel training and record-keeping, poorly established equipment cleaning procedures, and failure to assure in-process materials conform to specifications through proper testing. These observations highlight critical gaps in the company's quality management system.
Open in Dashboard
ID · 9eff666e-9662-4a10-aa64-6820f3666c60